Herpesviridae

Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update

Retrieved on: 
Friday, April 29, 2022
Health, Medical Devices, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, Aureus, Sepsis, Parasitism, Virus, Infection, Patent, FDA, Therapy, ALK, Neuroblastoma, JT Group Limited, Staphylococcus aureus, Single, SEC, Safety, EGFR, Klebsiella pneumoniae, Large-cell lung carcinoma, Patient, Research, IND, Degenerative disease, Bacteria, Clinical trial, Biomarker, Company, Inflammatory Bowel Diseases, Methicillin, Technology, Trial of the century, Prospectus, Febrile neutropenia, Methicillin-resistant Staphylococcus aureus, Euronext Paris, Lists of diseases, Lead, Escherichia coli, COVID-19, University, Staphylococcus, US, United States patent law, Rheumatoid arthritis, MRSA, Investment, Income, Diagnosis, KRAS, Lupus, Fungus, Pharmaceutical industry, Vaccine, Science, Herpesviridae, EU

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or We), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or We), a clinical stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology, autoimmune diseases and infectious diseases, today announced financial results for the fiscal year ended December 31, 2021, and provided an update on clinical and corporate developments.
  • Mr. Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented Aptorums operational plans remain on track.
  • Aptorum Group reported a net loss of $27.1 million in 2021, as compared to net income of $4.9 million in 2020.
  • Aptorum Group assumes no obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology

Retrieved on: 
Monday, January 10, 2022
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, SEC, JT Group Limited, DNA, Disease, Bacteria, Klebsiella pneumoniae, Febrile neutropenia, Technology, Patient, Research, Fungus, Parasitism, RNA, Bias, Lists of diseases, Infection, Euronext Paris, Diagnosis, Prospectus, Escherichia coli, Therapy, Virus, DNA sequencing, Mortality, Vaccine, Science, EU, Herpesviridae, Aptorum’s Rapid Pathogen Identification and Detection Diagnostics Technology (RPIDD), Aptorum Group Limited, APTORUM’S RAPID PATHOGEN IDENTIFICATION AND DETECTION DIAGNOSTICS TECHNOLOGY (RPIDD), APTORUM GROUP LIMITED

Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical stage biopharmaceutical company focused on novel technologies including treatments and diagnosis of infectious diseases, announced that its subsidiary company, Aptorum Innovations Holding Limited (Aptorum Innovations), has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology (RPIDD) for the diagnosis of pathogens including viruses, bacteria, fungi and parasites.

Key Points: 
  • Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (Aptorum Group or Aptorum), a clinical stage biopharmaceutical company focused on novel technologies including treatments and diagnosis of infectious diseases, announced that its subsidiary company, Aptorum Innovations Holding Limited (Aptorum Innovations), has commenced clinical validation of its molecular based rapid pathogen diagnostics liquid biopsy technology (RPIDD) for the diagnosis of pathogens including viruses, bacteria, fungi and parasites.
  • Mr Ian Huen, Chief Executive Officer and Executive Director of Aptorum Group, commented: We are very pleased to announce this exciting update on our RPIDD technology.
  • The high sensitivity and specificity demonstrated so far further support our objective to deliver a rapid, accurate and cost-effective liquid biopsy-based technology for infectious disease diagnostics.
  • We hope that RPIDD will revolutionize traditional first line clinical diagnostics approaches that are time consuming or that fail to detect or identify disease causing pathogens.

Rational Vaccines names Dr. Konstantin Kousoulas Vice President of Scientific Affairs

Retrieved on: 
Friday, February 26, 2021
Medical specialties, Virology, Viral diseases, Sexually transmitted diseases and infections, Microbiology, Herpes, Biology of bipolar disorder, Herpes simplex, HSV-2, Herpes virus, Herpesviridae, Vaccine

CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.

Key Points: 
  • CAMBRIDGE, Mass., Feb. 26, 2021 /PRNewswire/ --Leading virologist Konstantin "Gus" Kousoulas joined Rational Vaccines as vice president of Scientific Affairs where he will work to further the company's core mission of eradicating the world of the herpes simplex virus (HSV), the company announced today.
  • His addition to the team brings us one step closer to our goal of eradicating the Herpes pandemic."
  • Kousoulas' research focuses primarily on the molecular biology and the immunopathogenesis of human herpes viruses.
  • Rational Vaccines develops rationally engineered, live attenuated viral immunotherapeutic and prophylactic vaccine candidates, particularly focused on combating all diseases resulting from herpes simplex virus 1 (HSV-1) and herpes simplex virus 2 (HSV-2) infections.

Herpesviruses Hedge Their Bets to Optimize Survival

Retrieved on: 
Monday, July 6, 2020
Viruses, Branches of biology, Viral diseases, Microbiology, Betaherpesvirinae, Infectious causes of cancer, Animal virology, Herpesviridae, Dormancy, Organ transplantation, Herpes virus, Cytomegalovirus

However, in some the virus emerges from dormancy; for example in babies and in transplant recipients, and it causes serious problems and even death.

Key Points: 
  • However, in some the virus emerges from dormancy; for example in babies and in transplant recipients, and it causes serious problems and even death.
  • Indeed, cytomegalovirus is the leading cause of birth defects and the leading cause of transplant failures.
  • Although there were established examples of plants "hedging their bets" by producing a variety of seeds that can survive in different conditions, the work was the first example of a virus using latency to hedge bets.
  • "We'd like to see if our new findings could lead to new approaches to treating latent herpesviruses," says Chaturvedi.

Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Herpesviridae, Viruses, Medical specialties, Infectious causes of cancer, Viral proteins, Lymphoma, Epstein–Barr virus, Epstein–Barr virus infection, Epstein-Barr virus-associated lymphoproliferative diseases

The nanatinostat and valganciclovir combination in EBV-associated lymphomas is being investigated in an ongoing Phase 2 clinical trial.

Key Points: 
  • The nanatinostat and valganciclovir combination in EBV-associated lymphomas is being investigated in an ongoing Phase 2 clinical trial.
  • Approximately 95% of the world's adult population is infected with Epstein-Barr Virus (EBV), yet infections are commonly asymptomatic.
  • Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patients' life.
  • The Company's proprietary lead molecule, nanatinostat, is currently being evaluated in combination with valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas.

Alzheimer's Disease Virus Research Spotlighted at HHV-6 Conference, Reports Dr. Leslie Norins of Alzheimer's Germ Quest, Inc.

Retrieved on: 
Monday, July 8, 2019
Viruses, Betaherpesvirinae, Human herpesvirus 6, Infectious causes of cancer, Viral diseases, Herpesviridae, HHV, Immune system disorders, Dharam Ablashi

"It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.

Key Points: 
  • "It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.
  • He adds, "The entire spectrum of HHV-6 and its relatives' involvement in other 'mystery illnesses' is also intriguing".
  • He credits the HHV-6 Foundation, and its co-founder/executive director, Kristin Loomis, with helping to maintain interest in this group of herpesviruses.
  • Sinai, New York), who reviewed his research on HHV-6 in Alzheimer's brains, co-authored by Dr. Ben Readhead (Arizona State University) and several others.

Alzheimer's disease virus research spotlighted at HHV-6 conference, reports Dr. Leslie Norins of Alzheimer's Germ Quest, Inc.

Retrieved on: 
Monday, July 8, 2019
Viruses, Betaherpesvirinae, Human herpesvirus 6, Infectious causes of cancer, Viral diseases, Herpesviridae, HHV, Immune system disorders, Dharam Ablashi

"It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.

Key Points: 
  • "It was another sign that microbiological agents, including HHV-6, are finally beginning to receive the increased scrutiny in Alzheimer's disease research they've deserved for many years," says Dr. Norins.
  • He adds, "The entire spectrum of HHV-6 and its relatives' involvement in other 'mystery illnesses' is also intriguing."
  • He credits the HHV-6 Foundation , and its co-founder/executive director, Kristin Loomis, with helping to maintain interest in this group of herpesviruses.
  • Sinai, New York), who reviewed his research on HHV-6 in Alzheimer's brains, co-authored by Dr. Ben Readhead (Arizona State University) and several others.

NanoViricides Reaches an Agreement on Terms of License for Shingles Virus Drug Development

Retrieved on: 
Tuesday, February 26, 2019
Chickenpox, Virology, Herpesviridae, Veterinary medicine, Sexually transmitted diseases and infections, Varicella zoster virus, RTT, Herpes simplex virus, Virus, Holden Special Vehicles, Herpes, Shingles

NanoViricides previously tested the nanoviricide drug candidates being developed for HSV-1 against VZV in cell cultures and found them to be highly effective, in early 2017.

Key Points: 
  • NanoViricides previously tested the nanoviricide drug candidates being developed for HSV-1 against VZV in cell cultures and found them to be highly effective, in early 2017.
  • The Company continued further development of these drug candidates against VZV while it was continuing to develop new collaborations for animal testing of its HSV-1 and HSV-2 drug candidates.
  • In the past, TheraCour has never denied any licenses for any virus programs that we initiated, and therefore the Company continued its development of the VZV skin cream drug candidate.
  • The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them.